Latest News and Press Releases

UNO therapy results in a more immunogenic tumor microenvironment (TME) as well as a systemic response that overcomes anti-PD-1 resistance First-in-human Phase 1 clinical study is ongoing with...

50,000 or 100,000 ppm UNO alone or in combination with anti-mCTLA-4 more than tripled antigen specific central memory T-cell response versus anti-mCTLA-4 alone Pooled analysis of combination...

GARDEN CITY, N.Y., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on...

GARDEN CITY, N.Y. and HAMILTON, Bermuda, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Beyond Cancer, Ltd., an affiliate of Beyond Air, Inc. (NASDAQ: XAIR) that is developing ultra-high concentration nitric...

GARDEN CITY, N.Y., Oct. 02, 2023 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”) a commercial stage medical device and biopharmaceutical company focused on...

GARDEN CITY, N.Y. and HAMILTON, Bermuda, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Beyond Cancer, Ltd. (the “Company”), an affiliate of Beyond Air, Inc. (NASDAQ: XAIR) that is developing ultra-high...

New data demonstrates a therapeutic effect for at least 10 days after a single subcutaneously (SC) injection of an extended-release selective neuronal nitric oxide synthase (nNOS) inhibitor The...

Partnership provides access to hospitals in key Asia-Pacific countries Getz Healthcare will make a payment to Beyond Air upon receipt of CE Mark Beyond Air will receive royalty payments...

GARDEN CITY, N.Y., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”) a commercial stage medical device and biopharmaceutical company focused on...

GARDEN CITY, N.Y., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Reported commercial sales for LungFit® PH for the treatment of term and near-term neonates with hypoxic respiratory failure Currently have in...